Profluent Announces Publication of Generative AI Research in Nature with New Results for OpenCRISPR-1
Profluent, the AI-first protein design company, today announced a publication in Nature describing the design of OpenCRISPR-1, the world’s first AI-created genome editor to successfully edit the human genome. These findings validate the use of Profluent’s large language models (LLMs) to generate custom gene editors that match or exceed the performance of naturally occurring CRISPR systems, with the potential to expand gene editing capabilities and accelerate therapeutic development.
Profluent Introduces ProGen3, Demonstrating Scaling Laws for Foundation Models in Writing Biology
Profluent, the AI-first protein design company, today unveiled ProGen3, a family of frontier protein models. Trained on the world’s largest, highly curated dataset of protein sequences, the company’s foundation model for protein generation enables writing new biology to solve challenges across biomedicine, agriculture, and industrial applications.
Profluent Demonstrates AI Can Engineer Protein-DNA Interactions Without Iterative Laboratory Screening
Profluent, the AI-first protein design company, today announced Protein2PAM, the first in a series of AI models that will broadly focus on protein-DNA interactions. Trained on large, bioinformatically curated databases of mined biological sequences, Protein2PAM demonstrates the power of Profluent’s language models to reprogram complex biological systems without the need for wet laboratory evolution or structural modeling.
Profluent Successfully Edits Human Genome with OpenCRISPR-1, the World’s First AI-Created and Open-Source Gene Editor
Profluent, the AI-first protein design company, today debuted the OpenCRISPRTM initiative, releasing the world’s first open-source, AI-generated gene editor. With this launch, Profluent demonstrates the first successful precision editing of the human genome with customizable gene editors designed from scratch with AI.
Profluent Secures $35M in Additional Funding and Key Industry Experts to Scale Foundational AI Models for Biomedicine and Tackle First Vertical in Gene Editing
Profluent, an AI-first protein design company, today announced the close of additional funding to bring the total raised to $44M. The $35M financing was led by Spark Capital, with participation from existing investors Insight Partners and Air Street Capital along with a syndicate of angel investors from OpenAI, Salesforce, Octant Bio, and Google including Jeff Dean, Chief Scientist of Google DeepMind. The company previously raised $9M from Insight Partners, Air Street Capital, AIX Ventures, and Convergent Ventures.
